Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.

Nature communications - 13 Nov 2024

Alcalde-Herraiz Marta, Xie JunQing, Newby Danielle, Prats Clara, Gill Dipender, Gordillo-Marañón María, Prieto-Alhambra Daniel, Català Martí, Prats-Uribe Albert

Abstract excerpt

Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety remains unclear. We conducted a cis-Mendelian randomisation analysis to estimate the causal effect of sclerostin levels on cardiovascular risk factors. We meta-analysed three GWAS of sclerostin levels including 49,568 Europeans and selected 2 SNPs to be used as instruments. We included heel bone mineral density and hip...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Bone Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Diabetes Mellitus, Type 2

Share to Hip Fractures

Share to Mendelian Randomization Analysis

Share to Myocardial Infarction

Share to Osteoporotic Fractures

Source

Open in PubMed Open full text

Identifiers

PMID: 39537602
DOI: 10.1038/s41467-024-53623-5
PMCID: PMC11561231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.PMID 39537602Read ↗

The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular diseaseSemantic proximity Read ↗

Lifelong genetically lowered sclerostin and risk of cardiovascular diseaseSemantic proximity Read ↗

Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.Semantic proximity Read ↗

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationSemantic proximity Read ↗

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity Read ↗

A novel and efficient machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibitionSemantic proximity Read ↗

A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibition.Semantic proximity Read ↗

Sclerostin and Cardiovascular DiseaseSemantic proximity Read ↗

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in HumansSemantic proximity Read ↗

Cardio-metabolic-related plasma proteins reveal biological links between cardiovascular diseases and fragility fractures: a cohort and Mendelian randomisation investigationSemantic proximity Read ↗

Role of Sclerostin in Cardiovascular SystemSemantic proximity Read ↗

Genetic and atherosclerotic plaque immunohistochemical analyses do not associate reduced sclerostin expression with cardiovascular eventsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.